Noile-Immune Biotech (TSE:4893) GF Value Rank: 1 (As of Aug. 12, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4893 Noile-Immune Biotech Inc TSE:4893
46 GF Score
Price 円140.00
GF Value 円4.25
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Noile-Immune Biotech GF Value Rank?

Noile-Immune Biotech TSE:4893 -0.71% 46 GF Value Rank is 1 as of Aug. 12, 2026, which is at its 10-year median of 1.00. GuruFocus rates TSE:4893 with a GF Score™ of 46/100 and a GF Value™ of 円4.25 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Noile-Immune Biotech has the GF Value Rank of 1.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Noile-Immune Biotech GF Value Rank Related Terms


TSE:4893 vs VRTX, REGN, RVMD: GF Value Rank Comparison

For the Biotechnology subindustry, Noile-Immune Biotech's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Noile-Immune Biotech GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Noile-Immune Biotech's GF Value Rank falls into.


TSE:4893
46GF Score
Noile-Immune Biotech Inc TSE:4893
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 1 mean?
Noile-Immune Biotech (TSE:4893) has a GF Value Rank of 1 as of Aug. 12, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Noile-Immune Biotech and its competitors. This is near median its historical median of 1.00. Over the past decade, Noile-Immune Biotech's GF Value Rank has ranged from 1.00 to 1.00.
Is Noile-Immune Biotech's GF Value Rank too high?
Noile-Immune Biotech's current GF Value Rank of 1 is near median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 1.00. Overall, Noile-Immune Biotech has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's GF Value Rank compare to VRTX and REGN?
Noile-Immune Biotech's GF Value Rank of 1 can be compared against companies in the Biotechnology industry. Historically, Noile-Immune Biotech's own GF Value Rank has ranged from 1.00 to 1.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current GF Value Rank is 1, which is near median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.25, compared to a current price of 円140.00 — trading 3194.1% above its estimated fair value. The current GF Value Rank is 1, which is near median its 10-year median of 1.00. Noile-Immune Biotech's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current GF Value Rank is 1 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?

Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued. The current stock price of 円140.00 is trading 3194.1% above its estimated GF Value™ of 円4.25. GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.

Key valuation signals for TSE:4893:

  • GF Value Rank: 1 (near median its 10-year median of 1.00)
  • GF Value™: 円4.25 vs. price of 円140.00 (3194.1% above fair value)
  • GF Score™: 46/100 with 2 warning signs

No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Noile-Immune Biotech Business Description

Address 2-12-10 Shiba-Daimon, 5th Floor, T&G Hamamatsucho Building, Minato-ku, Yamaguchi, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
46GF Score

Get the complete analysis for TSE:4893

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円140.00
Price
円4.25
GF Value